Lactobacillus rhamnosus HN001 and Reduced Eczema Prevalence

• Effects of Lactobacillus rhamnosus HN001 in early life on the cumulative prevalence of allergic disease to 11 years

  • 2018-11-14
  • RCT
  • Pediatric Allergy and Immunology 29(8)
  • • K. Wickens
    • C. Barthow
    • E. Mitchell
    • Janice Kang
    • N. van Zyl
    • G. Purdie
    • T. Stanley
    • P. Fitzharris
    • R. Murphy
    • J. Crane

  • PubMed: 30430649
  • DOI: 10.1111/pai.12982

  8 Insights on

  • Reduced Eczema Prevalence

  • High evidence
  • Rigorous Journal

  Early childhood HN001 supplementation was associated with significant reductions in the 12-month prevalence of eczema at age 11 years (relative risk [RR] = 0.46, 95% CI 0.25-0.86, P = 0.015).

  Effect

  Beneficial

  Effect size

  Moderate

  Significant

  Yes

  Dose

  6 × 10^9 colony-forming units (cfu)

• A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years

  • 2012-06-15
  • RCT
  • Clinical & Experimental Allergy 42(7)
  • • K. Wickens
    • Peter N. Black
    • Thorsten Stanley
    • Edwin A. Mitchell
    • C. Barthow
    • P. Fitzharris
    • Gordon Purdie
    • Julian Crane

  • PubMed: 22702506
  • DOI: 10.1111/j.1365-2222.2012.03975.x

  3 Insights on

  • Reduced Eczema Prevalence

  • High evidence
  • Highly Cited

  The cumulative prevalence of eczema by 4 years (Hazard ratio (HR) 0.57 (95% CI 0.39-0.83)) ... were significantly reduced in the children taking HN001

  Effect

  Beneficial

  Effect size

  Large

  Significant

  Yes

  Dose

  6 × 10(9) cfu/day